Nuttall Musson, Ellen http://orcid.org/0000-0002-0395-3304
Miller, Rowan E.
Mansour, Marc R. http://orcid.org/0000-0001-6835-3791
Lockley, Michelle http://orcid.org/0000-0002-9281-5789
Ledermann, Jonathan A. http://orcid.org/0000-0003-3799-3539
Payne, Elspeth M. http://orcid.org/0000-0001-5841-778X
Article History
Received: 23 May 2023
Revised: 14 August 2023
Accepted: 13 September 2023
First Online: 17 November 2023
Competing interests
: REM: Consultancy fees: MSD, GSK, AZD, Ellipses, Shionogi and Clovis Oncology. Speakers’ bureau: Roche, GSK, AZD and Clovis Oncology. Travel grants: AZD and GSK. Trial funding: MSD. JL: Advisory board fees from Artios Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Merck Sharp & Dohme Corp, Nuvation. Steering/Data Monitoring Committee fees from Pfizer; Regeneron. Lecture fees from AstraZeneca, GlaxoSmithKline, and Neopharm; Clovis Oncology and Merck Sharp & Dohme Corp; Eisai. Institutional grants from AstraZeneca and MSD/Merck.